John Bertelson, MD
Behavioral Neurology & Neuropsychiatry · Austin, TXNPI 1215959697
Payments from drug & device makers
Across 585 payments — averaging $1143.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$247K
- Eli Lilly$179K
- E.r. Squibb & Sons, L.L.C.$177K
- Lilly USA, LLC$33K
- Biogen$26K
- Onmark, Inc.$1K
- plus $5K from 30 others
What the payments were for
- Consulting fees$23,3947%
- Speaking & faculty fees$257,95682%
- Travel & lodging$20,0046%
- Food & beverage$11,5584%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 291 | $246,530 |
| Eli Lilly | 5 | $178,861 |
| E.r. Squibb & Sons, L.L.C. | 2 | $176,948 |
| Lilly USA, LLC | 61 | $33,396 |
| Biogen | 26 | $26,374 |
| Onmark, Inc. | 1 | $1,400 |
| Corium, LLC | 10 | $1,134 |
| Johnson & Johnson | 28 | $554 |
| Lundbeck LLC | 24 | $553 |
| Acadia Pharmaceuticals Inc | 23 | $482 |
| Teva Pharmaceuticals USA, Inc. | 24 | $447 |
| Neurocrine Biosciences, Inc. | 18 | $437 |
| Otsuka America Pharmaceutical, Inc. | 16 | $358 |
| Axsome Therapeutics, Inc. | 8 | $189 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $157 |
| AbbVie | 6 | $135 |
| GE HealthCare | 3 | $110 |
| Amgen | 1 | $93 |
| EMD Serono, Inc. | 3 | $70 |
| Alkermes, Inc. | 3 | $65 |
| Vanda Pharmaceuticals Inc. | 3 | $51 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Grifols USA, LLC | 2 | $37 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Avanir Pharmaceuticals, Inc. | 2 | $30 |
| Life Molecular Imaging Ltd | 1 | $27 |
| Merz North America, Inc. | 1 | $24 |
| Almatica Pharma LLC | 1 | $22 |
| UCB, Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Abbott | 1 | $19 |
| AstraZeneca | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few behavioral neurology & neuropsychiatry providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NamzaricMemantine Hcl/Donepezil Hcl | 14 | $22,683 |
| Memantine Hcl ErMemantine Hcl | 194 | $14,846 |
| Rivastigmine | 59 | $7,460 |
| XareltoRivaroxaban | 13 | $6,702 |
| Donepezil Hcl | 158 | $1,990 |
| Memantine Hcl | 59 | $1,942 |
| Sertraline Hcl | 41 | $631 |
| Duloxetine Hcl | 31 | $612 |
| Escitalopram Oxalate | 74 | $534 |
| Divalproex Sodium ErDivalproex Sodium | 15 | $494 |
| Montelukast Sodium | 12 | $360 |
| Risperidone | 19 | $252 |
| Trazodone Hcl | 12 | $211 |
| Mirtazapine | 15 | $91 |
| Levothyroxine Sodium | 12 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieNamzaric | $135 | $22,68314 claims |
| Johnson & JohnsonXarelto | $554 | $6,70213 claims |
| Almatica Pharma LLCSertraline Hcl | $22 | $63141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in Texason file to place this against a meaningful peer group, so we don't.
Other behavioral neurology & neuropsychiatry in Austin
- Paul SchulzHouston$14.1M
- David HunterHouston$2.1M
- Gabriel de ErausquinSan Antonio$357K
- Alicia ParkerSan Antonio$203K
- Hilary ButellaThe Woodlands$34K
- Garima AroraSugar Land$5K
- Ricardo JorgeHouston$1K
- Melissa JonesHouston$885
- Tanveer KhanConroe$278
- Matthew AyersConroe$121
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.